Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Sparrow introduces clinical trial during Cancer Prevention Month - Spartan Newsroom
ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN
SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas
Managing Nonmetastatic Castration-resistant Prostate Cancer - European Urology
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
ARV-Trials.com
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Pivotal Trials Efficacy Data | For HCPs | REYVOW® (lasmiditan)
Treatment and trials in non-metastatic castration-resistant prostate cancer | Nature Reviews Urology
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book
Case 1: SPARTAN Trial for Apalutamide in nmCRPC
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
